Narumi Nakagiri
Stock Analyst at Daiwa
(2.50)
# 2,867
Out of 4,423 analysts
27
Total ratings
64.3%
Success rate
4.7%
Average return
Main Sectors:
Stocks Rated by Narumi Nakagiri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Upgraded: Buy | $94 → $155 | $161.93 | -4.28% | 3 | May 14, 2026 | |
| ABT Abbott Laboratories | Downgraded: Hold | $92 | $88.41 | +4.06% | 1 | Apr 21, 2026 | |
| PFE Pfizer | Downgraded: Hold | $34 → $27 | $25.21 | +7.10% | 4 | Feb 12, 2026 | |
| LLY Eli Lilly and Company | Upgraded: Buy | $700 → $1,230 | $1,098.57 | +11.96% | 3 | Dec 16, 2025 | |
| GILD Gilead Sciences | Upgraded: Buy | $128 | $123.76 | +3.43% | 1 | Aug 18, 2025 | |
| ABBV AbbVie | Upgraded: Buy | $180 → $214 | $216.49 | -1.15% | 3 | Aug 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Downgraded: Hold | $65 → $42 | $54.00 | -22.22% | 3 | Aug 5, 2025 | |
| EW Edwards Lifesciences | Upgraded: Buy | $89 | $87.36 | +1.88% | 1 | Jul 29, 2025 | |
| MRK Merck & Co. | Downgraded: Hold | n/a | $113.87 | n/a | 3 | Nov 11, 2024 | |
| JNJ Johnson & Johnson | Downgraded: Hold | $150 | $228.39 | n/a | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $252 → $320 | $337.60 | n/a | 3 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $210 | $451.63 | n/a | 1 | Jun 11, 2021 |
Illumina
May 14, 2026
Upgraded: Buy
Price Target: $94 → $155
Current: $161.93
Upside: -4.28%
Abbott Laboratories
Apr 21, 2026
Downgraded: Hold
Price Target: $92
Current: $88.41
Upside: +4.06%
Pfizer
Feb 12, 2026
Downgraded: Hold
Price Target: $34 → $27
Current: $25.21
Upside: +7.10%
Eli Lilly and Company
Dec 16, 2025
Upgraded: Buy
Price Target: $700 → $1,230
Current: $1,098.57
Upside: +11.96%
Gilead Sciences
Aug 18, 2025
Upgraded: Buy
Price Target: $128
Current: $123.76
Upside: +3.43%
AbbVie
Aug 7, 2025
Upgraded: Buy
Price Target: $180 → $214
Current: $216.49
Upside: -1.15%
Bristol-Myers Squibb Company
Aug 5, 2025
Downgraded: Hold
Price Target: $65 → $42
Current: $54.00
Upside: -22.22%
Edwards Lifesciences
Jul 29, 2025
Upgraded: Buy
Price Target: $89
Current: $87.36
Upside: +1.88%
Merck & Co.
Nov 11, 2024
Downgraded: Hold
Price Target: n/a
Current: $113.87
Upside: n/a
Johnson & Johnson
Jul 23, 2024
Downgraded: Hold
Price Target: $150
Current: $228.39
Upside: n/a
Dec 21, 2023
Upgraded: Buy
Price Target: $252 → $320
Current: $337.60
Upside: n/a
Jun 11, 2021
Downgraded: Hold
Price Target: $210
Current: $451.63
Upside: n/a